Cargando…

Combined Therapy with Intravenous Immunoglobulins, Letermovir and (Val-)Ganciclovir in Complicated Courses of CMV-Infection in Transplant Recipients

The treatment options for cytomegalovirus (CMV) infections in immunosuppressed patients are limited, mainly consisting of (val-)ganciclovir (VGC/GCV) as the first-line treatment. We report on three transplant recipients, one stem cell transplant (allo-HSCT) patient and two kidney transplant (KTx) re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Di Cristanziano, Veronica, Affeldt, Patrick, Trappe, Moritz, Wirtz, Maike, Heger, Eva, Knops, Elena, Kaiser, Rolf, Stippel, Dirk, Müller, Roman-Ulrich, Holtick, Udo, Scheid, Christoph, Kann, Martin, Kurschat, Christine E., Grundmann, Franziska
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8398864/ https://www.ncbi.nlm.nih.gov/pubmed/34442744 http://dx.doi.org/10.3390/microorganisms9081666

Ejemplares similares

CMV-IgG pre-allogeneic hematopoietic stem cell transplantation and the risk for CMV reactivation and mortality
por: Eberhardt, Kirsten Alexandra, et al.
Publicado: (2023)

Monitoring of hepatitis E virus RNA during treatment for chronic hepatitis E virus infection after renal transplantation
por: Affeldt, Patrick, et al.
Publicado: (2021)

Ganciclovir/letermovir: Rebound Cytomegalovirus hepatitis, acquired resistance to ganciclovir and nephrotoxicity: case report
Publicado: (2020)

Neutralizing response against SARS-CoV-2 Omicron BA.5 and XBB.1.5 in hemodialysis patients
por: Affeldt, Patrick, et al.
Publicado: (2023)

Use of letermovir‐valganciclovir combination as a step‐down treatment after foscarnet for ganciclovir‐resistant CMV infection in kidney transplant recipients
por: Rho, Elena, et al.
Publicado: (2021)

Emerging (val)ganciclovir resistance during treatment of congenital CMV infection: a case report and review of the literature
por: Morillo-Gutierrez, Beatriz, et al.
Publicado: (2017)

2121. The Impact of Donor CMV Serostatus on Outcomes of CMV Infections in the Era of Letermovir
por: Aramburo, Oscar Morado, et al.
Publicado: (2022)

1897. Letermovir Salvage for Complicated Cases of Resistant CMV
por: Turner, Nicholas, et al.
Publicado: (2018)

Suppression of CMV Infection with Letermovir in a Kidney Transplant Patient
por: Koepf, Uta S, et al.
Publicado: (2020)

Immune Response to Third and Fourth COVID-19 Vaccination in Hemodialysis Patients and Kidney Transplant Recipients
por: Affeldt, Patrick, et al.
Publicado: (2022)

Moving Past Ganciclovir and Foscarnet: Advances in CMV Therapy
por: Hakki, Morgan
Publicado: (2020)

1597. Risk Factors for Failure of Primary (Val)ganciclovir Prophylaxis Against Cytomegalovirus (CMV) Infection and Disease in Solid Organ Transplant (SOT) Recipients
por: Khurana, Mark Poulsen, et al.
Publicado: (2018)

A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation
por: Ljungman, Per, et al.
Publicado: (2020)

A Case of CMV Endotheliitis Treated with Intravitreal Ganciclovir Injection
por: Choi, Won Seok, et al.
Publicado: (2013)

Ganciclovir-resistant CMV (GCV-R CMV) Infection Leads to Poor Clinical Outcomes and Economic Burden of Ganciclovir-resistant Cytomegalovirus Infection in Lung Transplant Recipients
por: Patel, Twisha, et al.
Publicado: (2017)

Emergence and Persistence of Letermovir-Resistant Cytomegalovirus in a Patient With Primary Immunodeficiency
por: Popping, Stephanie, et al.
Publicado: (2019)

Efficacy and safety of topical ganciclovir in the management of cytomegalovirus (CMV)-related anterior uveitis
por: Wong, John X. H., et al.
Publicado: (2016)

Adoptive T-cell immunotherapy for ganciclovir-resistant CMV disease after lung transplantation
por: Holmes-Liew, Chien-Li, et al.
Publicado: (2015)

A Mortality Analysis of the Cytomegalovirus (CMV) Infection Letermovir Prophylaxis Trial in CMV-Seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation (HCT)
por: Maertens, Johan, et al.
Publicado: (2017)

CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients
por: Chavaz, Lara, et al.
Publicado: (2023)

580. Refractory and Resistant CMV Infections in Hematopoietic Cell Transplant Recipients in the Letermovir Primary Prophylaxis Era
por: Sassine, Joseph, et al.
Publicado: (2020)

922. The Impact of Clinically Significant CMV Infections on Other Viral Infections in the Era of Letermovir Primary Prophylaxis
por: Spallone, Amy, et al.
Publicado: (2021)

Efficacy and safety of an extemporaneous preparation of 2% ganciclovir eye drops in CMV anterior uveitis
por: Keorochana, Narumon, et al.
Publicado: (2017)

2296. Development of a Sequencing-Based Assay for Detection of CMV Antiviral Resistance Mutations to Letermovir in UL56
por: Grantham, James, et al.
Publicado: (2018)

1102. Reconstitution of CMV-specific cell-mediated immunity during letermovir prophylaxis in hematopoietic stem cell recipients
por: Abidi, Maheen, et al.
Publicado: (2020)

The promising efficacy of a risk-based letermovir use strategy in CMV-positive allogeneic hematopoietic cell recipients
por: Sourisseau, Mathilde, et al.
Publicado: (2022)

Resolution of Mild Ganciclovir-Resistant Cytomegalovirus Disease with Reduced-Dose Cidofovir and CMV-Hyperimmune Globulin
por: Patel, Samir J., et al.
Publicado: (2014)

Ganciclovir-Resistant CMV Colitis in a Donor-Seronegative/Recipient-Seronegative Liver Transplant Patient
por: Igbinedion, Samuel O., et al.
Publicado: (2018)

P1324: A RISK-BASED STRATEGY FOR THE USE OF LETERMOVIR IN CMV-POSITIVE RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
por: Beauvais, D., et al.
Publicado: (2022)

926. Risk factors for post-letermovir cytomegalovirus (CMV) reactivation in allogeneic hematopoietic stem cell transplant (HSCT) recipients
por: Mendoza, Maria Alejandra, et al.
Publicado: (2023)

RNAemia Corresponds to Disease Severity and Antibody Response in Hospitalized COVID-19 Patients
por: Eberhardt, Kirsten Alexandra, et al.
Publicado: (2020)

CMV Immunoglobulins for the Treatment of CMV Infections in Thoracic Transplant Recipients
por: Schulz, Uwe, et al.
Publicado: (2016)

Letermovir for cytomegalovirus prophylaxis
Publicado: (2019)

2122. The Impact of HHV-6 DNAemia on hematopoietic cell transplant (HCT) recipients at high risk for CMV reactivation in the era of Letermovir
por: Srinivasan, Krithia, et al.
Publicado: (2022)

Immune Responses to SARS-CoV-2 Infection and Vaccination in Dialysis Patients and Kidney Transplant Recipients
por: Affeldt, Patrick, et al.
Publicado: (2021)

Incidence of Ganciclovir Resistance in CMV-positive Renal Transplant Recipients and its Association with UL97 Gene Mutations
por: Aslani, Hamid Reza, et al.
Publicado: (2017)

Emergence of Letermovir-resistant HCMV UL56 mutant during rescue treatment in a liver transplant recipient with ganciclovir-resistant infection HCMV: a case report
por: Paolucci, Stefania, et al.
Publicado: (2021)

Stimulatory Effect of CMV Immunoglobulin on Innate Immunity and on the Immunogenicity of CMV Antigens
por: Deml, Ludwig, et al.
Publicado: (2021)

The Immunology of Posttransplant CMV Infection: Potential Effect of CMV Immunoglobulins on Distinct Components of the Immune Response to CMV
por: Carbone, Javier
Publicado: (2016)

194. Combinatorial Polyfunctionality Analysis of Antigen-specific T-cell Subsets (COMPASS) as a Predictor for Clinically Significant CMV Infection in the Letermovir Era
por: Zamora, Danniel, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_uaqksj3gag9r1qtm90udh0505a